Kyprolis

Active Ingredient(s): Carfilzomib
FDA Approved: * July 20, 2012
Pharm Company: * ONYX PHARMS INC
Category: Cancer

Carfilzomib, sold under the brand name Kyprolis, is an anti-cancer medication acting as a selective proteasome inhibitor. Chemically, it is a tetrapeptide epoxyketone and an analog of epoxomicin.[2] It was developed by Onyx Pharmaceuticals. The U.S. Food and Drug Administration (FDA) approved it on 20 July 2012, for use in people with multiple myeloma who have received at least two prior therapies, including treatment with bortezomib and an immunomodulatory therapy (such as le... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Kyprolis 60 mg/30ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 76075-101
Labeler:
Onyx Pharmaceuticals, Inc.
Kyprolis 30 mg/15ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 76075-102
Labeler:
Onyx Pharmaceuticals, Inc.
Kyprolis 10 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 76075-103
Labeler:
Onyx Pharmaceuticals, Inc.